Skip to Content

Entrectinib Pregnancy and Breastfeeding Warnings

Entrectinib is also known as: Rozlytrek

Medically reviewed by Drugs.com. Last updated on Oct 29, 2019.

Entrectinib Pregnancy Warnings

Animal studies during the period of organogenesis have revealed evidence of malformations at maternal exposures approximately 2.7 times the human exposure at the 600 mg dose. There are no controlled data in human pregnancy.

US FDA pregnancy category Not Assigned: The US FDA has amended the pregnancy labeling rule for prescription drug products to require labeling that includes a summary of risk, a discussion of the data supporting that summary, and relevant information to help health care providers make prescribing decisions and counsel women about the use of drugs during pregnancy. Pregnancy categories A, B, C, D and X are being phased out.

Use should be avoided.

US FDA pregnancy category: Not assigned.

Risk Summary: Based on literature reports in humans with congenital mutations leading to changes in TRK signaling, findings from animal studies, and its mechanism of action, this drug can cause fetal harm when administered to a pregnant woman.

Comments:
-This drug can harm a developing fetus.
-Verify negative pregnancy status in females of reproductive potential prior to initiating therapy.
-If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential harm to the fetus.
-Advise female patients of reproductive potential to use effective contraception during therapy and for at least 5 weeks after.
-Advise male patients with female partners of reproductive potential to use effective contraception during therapy and for 3 months after.

See references

Entrectinib Breastfeeding Warnings

Use is not recommended.

Excreted into human milk: Unknown
Excreted into animal milk: Data not available

Comments:
-The effects in the nursing infant are unknown.
-Because of the potential for adverse reactions in breastfed infants from this drug, advise lactating women to discontinue breastfeeding during therapy and for 7 days after.

See references

References for pregnancy information

  1. "Product Information. Rozlytrek (entrectinib)." Genentech, South San Francisco, CA.

References for breastfeeding information

  1. "Product Information. Rozlytrek (entrectinib)." Genentech, South San Francisco, CA.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.